|
[1] SEEGER C,MASON WS. Molecular biology of hepatitis B virus infection[J]. Virology,2015,479-480:672-686.
|
|
[2] WANG Z,HUANG Y,WEN S,et al. Hepatitis B virus genotypes and subgenotypes in China[J]. Hepatol Res,2007,37(s1):s36-s41.
|
|
[3] FANNING GC,ZOULIM F,HOU J,et al. Therapeutic strategies for hepatitis B virus infection:Towards a cure[J]. Nat Rev Drug Discov,2019,18(11):827-844.
|
|
[4] HOU JL,XU D,SHI G,et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B[J]. Adv Ther,2015,32(8):727-741.
|
|
[5] DEGASPERI E,VIGANO M,AGHEMO A,et al. PegIFN-α2a for the treatment of chronic hepatitis B and C:A 10-year history[J]. Expert Rev Anti Infect Ther,2013,11(5):459-474.
|
|
[6] VOLZ T,ALLWEISS L,BEN MBAREK M,et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus[J]. J Hepatol,2013,58(5):861-867.
|
|
[7] WEDEMEYER H,SCHONEWEIS K,BOGOMOLOV PO,et al.GS-13-Final results of a multicenter,open-label phase 2clinical trial(MYR203)to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection[J]. J Hepatol,2019,70(1):e81.
|
|
[8] SHIMURA S,WATASHI K,FUKANO K,et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity[J]. J Hepatol,2017,66(4):685-692.
|
|
[9] GALLAY P,URE D,BOBARDT M,et al. The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBs Ag in transgenic mice[J]. PLo S One,2019,14(6):e0217433.
|
|
[10] KUO J,BOBARDT M,CHATTERJI U,et al. A pan-cyclophilin inhibitor,CRV431,decreases fibrosis and tumor development in chronic liver disease models[J]. J Pharmacol Exp Ther,2019,371(2):231-241.
|
|
[11] China pharmaceutical Innovation Promotion Association,The world’s first release of 9 blockbuster new drugs domestic and foreign clinical research data stunningly unveiled[EB/OL]. http://www. phirda. com/artilce-8439. html? cld=8436.[2017-11-02].(in Chinese)中国医药创新促进会．全球首发9个重磅新药国内外临床研究数据惊艳亮相[EB/OL]. http://www. phirda. com/artilce_8439. html? cId=8436.[2017-11-02].
|
|
[12] REN Q,LIU X,LUO Z,et al. Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate(GLS4)[J]. Bioorg Med Chem,2017,25(3):1042-1056.
|
|
[13] ZHANG H,NIU JQ,DING HY,et al. Analysis of factors influencing the efficacy and safety of GLS4 treatment in patients with chronic hepatitis B[J]. Hepatology,2019,70(s1):688.
|
|
[14] BERKE JM,DEHERTOGH P,VERGAUWEN K,et al. Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379[J]. Antimicrob Agents Chemother,2020.[Online ahead of print]
|
|
[15] ZOULIM F,YOGARATNAM JZ,VANDENBOSSCHE JJ,et al. Safety,pharmacokinetics and antiviral activity of novel HBV capsid assembly modulator,JNJ-56136379,in patients with chronic hepatitis B[J]. Hepatology,2018,68(s1):74.
|
|
[16] GANE E,SCHWABE C,LENZ O,et al. JNJ-64530440(JNJ-0440),A novel,class N capsid assembly modulator(CAM-N):Safety,tolerability,pharmacokinetics and antiviral activity of multiple ascending doses in patients with chronic hepatitis B[J]. Hepatology,2019,70(s1):89.
|
|
[17] GANE E,LIU A,YUEN MF,et al. RO7049389,a core protein allosteric modulator,demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated[J].J Hepatol,2018,68:s101.
|
|
[18] GANE E,YUEN MF,BO Q,et al. FRI-219-RO7049389,a core protein allosteric modulator,demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients[J]. J Hepatol,2019,70(1):e491.
|
|
[19] YUEN MF,AGARWAL K,GANE EJ,et al. Safety,pharmacokinetics,and antiviral effects of ABI-H0731,a hepatitis B virus core inhibitor:A randomised,placebo-controlled phase 1 trial[J]. Lancet Gastroenterol Hepatol,2020,5(2):152-166.
|
|
[20] MA X,LALEZARI J,NGUYEN T,et al. LBO-06-Interim safety and efficacy results of the ABI-H0731 phase 2a program exploring the combination of ABI-H0731 with Nuc therapy in treatment-naive and treatment-suppressed chronic hepatitis B patients[J]. J Hepatol,2019,70(1):e130.
|
|
[21] SULKOWSKI MS,AGARWAL K,FUNG S,et al. Continued therapy with ABI-H0731+Nrt I results in sequential reduction/loss of HBV DNA,HBV RNA,HBe Ag,HBcrAg and HBs Ag in HBe Ag-positive patients[EB/OL]. AASLD,Boston,USA,November 8-12,2019:Poster LP1. https://investor.assemblybio. com/static-files/97f173d3-6aad-4f9c-bcfc-82cc80a9ead7.
|
|
[22] YUEN MF,AGARWAL K,GANE E,et al. The second-generation hepatitis B virus(HBV)core inhibitor(CI)ABI-H2158is associated with potent antiviral activity in a 14-day monotherapy study in HBe Ag-positive patients with chronic hepatitis B(CHB)[EB/OL]. AASLD,Boston,USA,November 8-12,2019:Poster LP14. https://investor. assemblybio. com/static-files/5b2547c8-53b1-4666-aaf5-ace722e3983e.
|
|
[23] HUANG Q,SIMON H,ZHOU Y,et al. PS-073-Preclinical profile of HBV core protein inhibitor,ABI-H3733,a potent inhibitor of cccDNA generation in HBV infected cells[J]. J Hepatol,2019,70(1):e48.
|
|
[24] CARTHEW RW,SONTHEIMER EJ. Origins and mechanisms of miRNAs and siRNAs[J]. Cell,2009,136(4):642-655.
|
|
[25] CROOKE ST,WITZTUM JL,BENNETT CF,et al. RNA-targeted therapeutics[J]. Cell Metab,2018,27(4):714-739.
|
|
[26] NIKAM RR,GORE KR. Journey of siRNA:Clinical developments and targeted delivery[J]. Nucleic Acid Ther,2018,28(4):209-224.
|
|
[27] GANE E,LOCARNINI S,LIM TH,et al. Dose response with the RNA interference therapy JNJ-3989 combined with nucleos(t)ide analogue treatment in expanded cohorts of patients with chronic hepatitis B[EB/OL]. AASLD,Boston,USA,November 8-11,2019. https://ir. arrowheadpharma. com/static-files/66178cc7-10ce-4db2-8400-1c0495271e35.
|
|
[28] YUEN MF,LOCARNINI S,GIVEN B,et al. First clinical experience with RNA interference-based triple combination therapy in chronic hepatitis B:JNJ-3989,JNJ-6379 and a nucleos(t)ide analogue[EB/OL]. AASLD,Boston,USA,November8-11,2019. https://ir. arrowheadpharma. com/static-files/6d7edbe7-c5a2-46c5-9990-a9cdfec854a9.
|
|
[29] HAN K,CREMER J,ELSTON R,et al. A randomized,double-blind,placebo-controlled,first-time-in-human study to assess the safety,tolerability,and pharmacokinetics of single and multiple ascending doses of GSK3389404 in healthy subjects[J]. Clin Pharmacol Drug Dev,2019,8(6):790-801.
|
|
[30] YUEN MF,HEO J,JANG JW,et al. Phase 2a,randomized,double-blind,placebo-controlled study of an antisense inhibitor(ISIS 505358)in treatment-nave chronic hepatitis B(CHB)patients:Safety and antiviral efficacy[EB/OL].AASLD,Boston, USA, November 8-12,2019. https://www. natap. org/2019/AASLD/AASLD_34. htm.
|
|
[31] YUEN MF,HEO J,KUMADA H,et al. Results after 12 weeks treatment of multiple doses of GSK3389404 in chronic hepatitis B subjects on stable nucleos(t)ide therapy in a phase 2a double-blind,placebo-controlled study[EB/OL]. AASLD,Boston,USA,November 8-12,2019. https://www. natap.org/2019/AASLD/AASLD_33. htm.
|
|
[32] ROCHE. Roche to acquire Santaris Pharma to expand discovery and development of RNA-targeting medicines[EB/OL].[2014-08-04]. https://www. roche. com/media/releases/med-cor-2014-08-04. htm.
|
|
[33] HAN X,ZHOU C,JIANG M,et al. Discovery of RG7834:The first-in-class selective and orally available small molecule hepatitis B virus expression inhibitor with novel mechanism of action[J]. J Med Chem,2018,61(23):10619-10634.
|
|
[34] VAILLANT A. REP 2139:Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection[J]. ACS Infect Dis,2019,5(5):675-687.
|
|
[35] ROEHL I,SEIFFERT S,BRIKH C,et al. Nucleic acid polymers with accelerated plasma and tissue clearance for chronic hepatitis B therapy[J]. Mol Ther Nucleic Acids,2017,8:1-12.
|
|
[36] BAZINET M,PANTEA V,PLACINTA G,et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165,tenofovir disoproxil,and pegylated interferon alfa-2a in patients with chronic HBV infection nave to nucleos(t)ide therapy[J]. Gastroenterology,2020.[Oline ahead of print]
|
|
[37] BAZINET M,PANTEA V,PLACINTA G,et al. Achieving functional cure of HBV and HBV/HDV co-infection with REP2139:Completed follow-up in the REP 401 and REP 301-LTF studies[EB/OL]. HepDART,Kauai,Hawaii,USA,December 8-12,2019. http://replicor. com/wp-content/uploads/2019/12/Replicor-REP-401-301-LTF-Completefollow-up-poster-P15-HEPDART-2019-FINAL. pdf
|
|
[38] GANE EJ,LIM YS,GORDON SC,et al. The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection[J]. J Hepatol,2015,63(2):320-328.
|
|
[39] AGARWAL K,AHN SH,ELKHASHAB M,et al. Safety and efficacy of vesatolimod(GS-9620)in patients with chronic hepatitis B who are not currently on antiviral treatment[J]. J Viral Hepat,2018,25(11):1331-1340.
|
|
[40] LI C,HERSCHKE F,CREUS AD,et al. P1-015:Oral administration of JNJ-4964(AL-034/TQ-A3334),a selective toll-like receptor 7 agonist,in AAV/HBV mice for 12 weeks,resulted in potent and sustained anti-HBV activity with HBs Ag seroconversion and detectable HBs Ag-specific T cells and B cells[J]. J Viral Hepat,2018,25(s2):40.
|
|
[41] GANE E,PASTAGIA M,CREUS AD,et al. FRI-198-A Phase,double-blind,randomized,placebo-controlled,first-in-human study of the safety,tolerability,pharmacokinetics and pharmacodynamics of oral JNJ-64794964,a tolllike receptor-7 agonist,in healthy adults[J]. J Hepatol,2019,70(1):e478.
|
|
[42] GANE E,ZHAO Y,TAN SK,et al. Efficacy and safety of oral TLR8 agonist selgantolimod in virally suppressed adult patients with chronic hepatitis B:A phase 2,randomized,doubleblind, placebo-controlled, multicenter study[EB/OL].AASLD, Boston, USA, November 8-12,2019. https://www. natap. org/2019/AASLD/AASLD_79. htm
|
|
[43] GILMORE S,TAM D,DICK R,et al. Antiviral activity of GS-5801,a liver-targeted prodrug of a lysine demethylase 5 inhibitor,in a hepatitis B virus primary human hepatocyte infection model[J]. J Hepatol,2017,66(1):s690-s691.
|
|
[44] LIU H,HOU J,ZHANG X. Targeting cIAPs,a new option for functional cure of chronic hepatitis B infection?[J]. Virol Sin,2018,33(5):459-461.
|
|
[45] ERKEN R,STELMA F,ROY E,et al. First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001[J]. J Hepatol,2018,68(s1):s488-s489.
|
|
[46] BLOOM K,MAEPA MB,ELY A,et al. Gene therapy for chronic HBV-Can we eliminate cccDNA?[J]. Genes(Basel),2018,9(4):e207.
|
|
[47] BERTOLETTI A,TAN AT,KOH S. T-cell therapy for chronic viral hepatitis[J]. Cytotherapy,2017,19(11):1317-1324.
|
DownLoad: